You could look at a half dozen small bio companies and see the same things come up. Its the shorts, wall street, BP, fudsters, etc. Call me naive but sometimes its just a small bio trying to enter the big boys arena and its not easy. I will say PPHM has had their share of setbacks and the dose switching does reek but we will overcome it. ROCHE isn't so powerful they can stymie us. I would say they are the most likely candidate to partner with but price must be a problem with the current data.
I believe PPHM knows it has a powerful platform with BAVI but BP will not pay the price without more data. They won't pay 5-20x our market cap without confirmed data so we have a standoff. We have Bavi, the patents, AVID, cotara, the star studded clinical team (Garnick). We have no debt....that is huge and we own 100% of everything. It has cost us in dilution but if you have used our current low price to add you can maintain your % ownership even with the dilution. I don't think we are selling at these prices. If Ayer is in fact closing shop getting out of their PPHM stock could be putting downward pressure on the stock.
Its not easy to stay patient as we wait on the data for 1st line NSCLC. To me the longer we wait the better the data gets. We'll get the data out, hopefully stellar, and sell 10M shares at 4-6/sh. If we can't come to terms with Roche or another BP we go it alone. Dendreon did it with their immunotherapy drug Provenge. They were able to launch Provenge but stumbled badly in assessing the market and sell through. Its also has over a third of its shares held by shorts.
With ASCO, 1st line, Ph3 on 2nd line, we have some good stuff to look forward to. Sit back, add if you can, and enjoy your life. Thorpe's passing at 61 and the horrific bombings in Boston are reminders how quick things in life can change.
Boston strong,
eastcoastguy
News 
Market Data 
Discover 
AI
